ABSTRACT

Pycnogenol is a standardized extract from the bark of the French maritime pine. The aim of the present systematic review and meta-analysis was to clarify the effect of Pycnogenol supplementation on C-reactive protein (CRP) concentration. To identify eligible studies in order to find clinical trials which examined the effect of Pycnogenol supplementation on the level of CRP in adult participants, PubMed, Scopus, and Google Scholar were systematically searched until December 2017. Mean of CRP was collected to estimate the effect size of the supplementation. Potential sources of heterogeneity were explored by subgroup analysis. Five trials including 324 participants were included in this meta-analysis. Pooled effect size showed significant effect of Pycnogenol supplementation on CRP (−1.22 mg/dL, 95% confidence interval, −2.43, −0.003; I² = 99%, p < 0.001). When the meta-analysis was subgrouped by dose of Pycnogenol, heterogeneity was attenuated in > 150 mg/d category (I² = 0.0%, p = 0.42). There was significant difference between-subgroup heterogeneity (p < 0.001). Furthermore, no evidence of publication bias for CRP (p = 0.27, Begg’s test and p = 0.62, Egger’s test) was seen. Present systematic review and meta-analysis suggested Pycnogenol consumption can decrease the level of CRP and have anti-inflammatory effect. So, Pycnogenol as an anti-inflammatory agent might be a priority in interventions. Further studies with large-scale and better design are needed to confirm this result.

Keywords: Pycnogenols; C-reactive protein; Inflammation; Meta-analysis
INTRODUCTION

Recently there has been growing attention on the use of nutritional supplements, which have become an inseparable part of people’s lifestyle worldwide [1]. These supplements are consumed to compensate for nutritional deficiencies or to treat in various diseases [2].

Pycnogenol as a standardized extract from the bark of the French maritime pine (Pinus pinaster Aiton subsp. Atlantica), is one of the most famous herbal dietary supplements with antioxidant and anti-inflammatory effects [3,4]. In the American and European traditional medicine, the use of the non-standardized extract was common as an anti-inflammatory agent to alleviate the symptoms of scurvy [5,6]. Pycnogenol contains 2 types of flavonoids [4]: polymeric flavonoids (65% ± 75%), such as procyanidins, catechins and epicatechins, and varying change in length and the others with less quantities are monomeric flavonoids, such as gallic acid, caffeic acid, and ferulic acid [4]. The presence of these compounds in the Pycnogenol structure caused the antioxidant and anti-inflammatory effects of this supplement [3]. The antioxidant effects of Pycnogenol are include scavenging of free radicals, metal chelation, and activation of lipid peroxidation-preventing enzymes [3,7,8].

Inflammation is a response to conditions such as infection and tissue injury [9]. It causes elevation in the level of inflammatory factors such as C-reactive protein (CRP) [10]. CRP is a positive acute-phase protein, whose plasma concentration increases in response to inflammation, and is related to the risk of serious diseases including cardiovascular events, and myocardial infarction and stroke [11]. The increase in CRP level occurs due to the elevation in proinflammatory cytokines such as interleukin-6 (IL-6), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α) [12]. The direct effects of CRP on nuclear factor-kappa B (NF-κB) activation are already determined. In addition, most inflammatory responses depend to NF-κB activation [13].

Some pioneering studies demonstrated that Pycnogenol supplementation can down-regulate the NF-κB pathway and reduce the production of the proinflammatory cytokines TNF-α and IL-1β [14]. Other studies have shown that Pycnogenol extracts have desirable effects in lowers fasting plasma glucose [15], lipids profile [16], and antioxidant levels [17]. It has also been proved that Pycnogenol has inhibitory effects on cyclooxygenases (COX-1 and COX-2) [18]. Controversial results due to Pycnogenol consumption on CRP levels were reported recently [19]. Because of this disagreement, in this meta-analysis, we examined the clinical evidence for the effect of Pycnogenol supplementation on CRP levels among adult subjects of both sexes to evaluate the anti-inflammatory effect of Pycnogenol. CRP was chosen because it’s a systematic inflammation indicator and is an important risk factor that associated with chronic disorders [20].

MATERIALS AND METHODS

Search strategy

This study designed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [21]. Four following databases were systematically searched from their earliest online available date up November 30, 2017: MEDLINE (http://www.ncbi.nlm.nih.gov/pubmed), Scopus (http://www.scopus.com), Google Scholar (http://scholar.google.com), and Web of Science (http://www.webofscience.com). The one-handed
search methodology was performed to achieve all potential studies based on pre-defined search keywords (Pine bark extract or PBE or Pycnogenol or French maritime) without any restrictions for language and time. In order to increase the search accuracy, the wild-card term “*” was applied. In addition, to collect further relevant papers we searched trials registers platform, specifically ClinicalTrials.gov website, and hand-scanned the reference lists of all selected articles or any identified review studies.

**Study selection**

After the exclusion of duplicate publications in the first screening, 2 investigators (MP and ON) separately appraised the titles and abstracts of all records to identify eligible studies. In cases where the abstract of an article was not sufficient for the investigators to decide its relevance, the full texts of the selected papers were carefully reviewed to determine eligible manuscripts. Any disagreement on the selection was settled by face-to-face discussion between the 2 investigators until a consensus was reached. Finally, all trials that investigated the efficacy of Pycnogenol supplements on CRP level were included in this systematic review and meta-analysis. Exclusion criteria were as follows: 1) studies that investigated only a specific content of Pycnogenol instead of the whole substance; 2) Pycnogenol was part of a multi-herbal treatment; 3) studies which lacked a suitable control group; 4) trials involving subjects aged less than 18 years; and 5) publications with no available full-text and no response from the corresponding author.

**Data extraction and assessment of quality**

The full text of eligible studies were scrutinized by 2 independent authors (MP and ON) and the following information was extracted using a pre-designed data collection form: 1) the first author’s last name, country, and year of publication; 2) number, sex, and mean age of the study participants; 3) study design; 4) duration of treatment; 5) method of administration in the comparison arm; 6) type of intervention in the active arm; 7) doses of Pycnogenol administered; 8) note about subjects; and 9) main outcomes.

The methodological quality of included publications in this systematic review was ascertained by using the quantitative 5-point Jadad scale [22]. This validated checklist incorporates the following 3 major parts: randomization concealment (0–2 points), blinding (0–2 points), and dropout rate (0–1 point). Based on the responses to these items, studies with Jadad score equal or greater than 3 were regarded as high quality. Otherwise, the paper was considered low quality. There was little disagreement between the 2 assessors over data extraction and quality assessment, which these discrepancies were resolved by a senior author (HM).

**Statistical analysis**

Effect size was assessed by the following formula:

\[
\text{Effect size} = \frac{\text{(post-intervention value in the treatment group) - (pre-intervention value in the treatment group)}}{\text{(post-intervention value in the control group) - (pre-intervention value in the control group)}}
\]

To calculate pooled effect size for CRP, we used random effects model. Between-study heterogeneity was evaluated using I-square ($I^2$) test. A significance level of $I^2 > 40\%$ was considered as clinically important heterogeneity [23]. To find the potential sources of between-study heterogeneity, we carried out a pre-planned subgroup analysis based on
dose of Pycnogenol, mean age of participants, study duration and participants' condition.
Heterogeneity between subgroups was evaluated using fixed-effect model. We used Begg's
rank correlation test and Egger's regression asymmetry test to evaluate publication bias.
Statistical analysis was performed using STATA 11.2 software (StataCorp, College Station,
TX, USA). The p values < 0.05 were considered statistically significant.

RESULTS

Included studies
Of 1,306 articles identified from PubMed and EMBASE, 1,277 papers were excluded
because of duplication, obvious irrelevance, and the inconsistency in the inclusion criteria.
Twenty-four articles were excluded after full-text evaluation (no implied outcome [n = 13],
uncontrolled design [n = 2], use of a mixture of Pycnogenol with other substances [n = 7],
and animal studies [n = 2]). Finally, 5 randomized controlled trials (RCTs) [16,17,24-27] met
all the inclusion and exclusion criteria. The study identification and selection process are
illustrated in Figure 1.

Study characteristics
Characteristics of the eligible studies are summarized in Table 1. A total of 324 subjects
were included in the analysis. Publication dates of articles ranged from 2008 to 2017. The
trial designs were parallel in 4 studies [16,17,24,25] and was cross-over in 1 [19]. The follow-

---

| Identification | Articles identified through databases searching (n = 1,306) |
|----------------|---------------------------------------------------------|
|                | Records after duplicates removed (n = 1,069)            |
|                | Records screened (n = 1,069)                           |
|                | Records excluded (n = 1,040)                           |
|                | - Unrelated studies (n = 755)                          |
|                | - Animal or in vitro studies (n = 127)                 |
|                | - In vitro studies (n = 36)                            |
|                | - Review articles (n = 122)                            |
|                | Full-text articles assessed for eligibility (n = 29)    |
|                | Full-text articles excluded (n = 24)                   |
|                | - Not implying outcome (n = 13)                        |
|                | - Not having a controlled design (n = 2)               |
|                | - Use the mixture of pomegranate with other substance (n = 7) |
|                | - Animal studies (n = 2)                              |
|                | Included studies in qualitative synthesis (n = 5)      |
|                | Included studies in quantitative synthesis (meta-analysis) (n = 5) |

Figure 1. PRISMA flow diagram of study selection process.
PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
up ranged from 8 weeks to 6 months. Selected studies were conducted in perimenopausal women [16], subjects with hypertension [24], osteoarthritis [17], coronary artery disease [19], and individuals with increased cardiovascular disease (CVD) risk [25]. The summary of the quality assessment of each study is presented in Table 2. The control groups of 3 were randomized by a blinding method. Two studies did not use a randomized controlled design. Most of the studies had a few dropouts. Therefore, 3 trials earned a score of 5 and were considered of as a high quality, whereas 2 studies received a score of 1 and were considered to be of low quality. Two studies investigated Pycnogenol at a dose of 100 mg/d, one study investigated Pycnogenol at a dose of 150 mg/d, and 2 studies investigated Pycnogenol at a dose of 200 mg/d. In 4 studies administered Pycnogenol tablets at a dose of 50 mg to achieve the final dose, whereas in one study, Pycnogenol was administered as a single dose of 300 mg and repeated doses of 200 mg [19].

Effect of Pycnogenol supplementation on CRP
Pooled effect size showed significant effects of Pycnogenol supplements on CRP (−1.22 mg/dL, 95% confidence interval [CI], −2.43, −0.003) (Figure 2). Due to a significant heterogeneity between studies ($F = 99\%$, $p < 0.001$), subgroup analyses were performed based on the dose of Pycnogenol (> 150 mg/d vs. ≤ 150 mg/d), mean age of participants (> 55 years vs. ≤ 55 years), study duration (> 12 weeks vs. ≤ 12 weeks), and participants’ condition (with CVD vs. without CVD; Table 3). When the meta-analysis was subgrouped by the dose of Pycnogenol (Figure 2), heterogeneity was attenuated in the > 150 mg/d category (−0.094 mg/dL, 95% CI, −0.19, 0.009; $F = 0.0\%$, $p = 0.42$). There was significant heterogeneity between the subgroups ($p < 0.001$) and no evidence of publication bias among the studies examining the effect of Pycnogenol on CRP ($p = 0.27$, Begg’s test and $p = 0.62$, Egger’s test).

| Table 1. Data extraction of selected studies |
|---------------------------------------------|
| **First author (publication year)** | **Country** | **Number and gender** | **Mean age, yr** | **Clinical Trial design/randomized/blinding** | **Duration** | **Comparison group** | **Intervention group** | **Pycnogenol dosage, mg/day** | **Jadad score** | **Notes about participants** | **Results** |
|---------------------------------------------|
| Luzzi (2017) [16] | Italy | 70 (female) | 44.0 | Parallel/ns/ns | 6 mon | Menopausal best management | Menopausal best management + Pycnogenol tablets | 100 | 1 | Healthy perimenopausal women | CRP ↓ |
| Belcaro (2008) [17] | Germany | 55 (both gender) | 51.7 | Parallel/randomized/doubled blinded | 3 mon | Placebo | Pycnogenol tablets | 100 | 5 | Osteoarthritis | CRP ↓ |
| Enseleit (2012) [19] | Switzerland | 23 (both gender) | 63.1 | cross-over/randomized/double blinded | 8 wk | Placebo or vice versa | Pycnogenol | 200 | 5 | Coronary artery disease | CRP ++ |
| Drieling (2010) [25] | USA | 121 (both gender) | 55.4 | Parallel/randomized/double blind | 12 wk | Placebo | Pycnogenol | 200 | 5 | Individuals with increased CVD risk | CRP ↓ |
| Cesarone (2010) [24] | Italy | 55 (both gender) | 53.5 | Parallel/ns/ns | 6 mon | 10 mg ramipril | Ramipril plus Pycnogenol | 150 | 1 | Hypertensive patients, symptomatic for CVD | CRP ↓ |

**ns, not significant; CVD, cardiovascular disease; CRP, C-reactive protein.**

| Table 2. Risk of bias assessment of included studies |
|---------------------------------------------|
| **Author (Year)** | **Randomization** | **Methodology of randomization** | **Blinding** | **Methodology of blinding** | **Withdrawal of participants** | **Overall score** |
|---------------------------------------------|
| Luzzi (2017) | - | - | - | - | - | 1 |
| Belcaro (2008) | - | - | - | - | - | 5 |
| Enseleit (2012) | - | * | - | - | - | 5 |
| Drieling (2010) | * | * | * | * | * | 5 |
| Cesarone (2010) | - | - | - | - | - | 1 |
DISCUSSION

To our knowledge, the present meta-analysis is the first to assess the effect of Pycnogenol on CRP concentration. Results obtained from RCTs in this meta-analysis showed that Pycnogenol had a significant effect on lowering CRP concentration. However, due to high heterogeneity, these results should be interpreted with caution. The subgroup analysis also revealed that the heterogeneity was attenuated in the > 150 mg/d and > 55 years subgroups.

CRP is known as a valuable marker for the identification and evaluation of disease progression or the efficacy of treatment among clinicians. The mechanism underlying Pycnogenol effect for management of CRP levels is unknown. It seems to be related with the modulation of other proinflammatory factors and proinflammatory cytokines.

Activation of the transcription factor NF-κB significantly increased the production and release of proinflammatory cytokines including IL-1β, IL-6, and TNF-α. Particularly, it can be said that the most proinflammatory genes expression are dependent on NF-κB activation [26]. The active form of NF-κB are nuclear homo- or heterodimeric complexes. Most of the dimers are formed of P50 and P65 subunits and p65 is their main transcriptional activator [27].

Table 3. Subgroup analysis to assess the effect of Pycnogenol consumption on serum hs-CRP

| Categories          | Subgroups          | Effect size* | 95% CI                        | I-squared (%) | p for heterogeneity | p for between subgroup heterogeneity |
|---------------------|--------------------|--------------|-------------------------------|---------------|---------------------|-------------------------------------|
| Dose, mg/d          | > 150 (2)          | −0.094       | −0.198, 0.009                 | 0.0           | 0.424               | < 0.001                             |
|                     | ≤ 150 (3)          | −1.816       | −2.809, −0.824                | 96.8          | < 0.001             |                                     |
| Duration, wk        | > 12 (2)           | −1.419       | −2.624, −0.214                | 96.1          | < 0.001             | < 0.001                             |
|                     | ≤ 12 (3)           | −1.076       | −3.041, 0.888                 | 99.3          | < 0.001             |                                     |
| Age, yr             | > 55 (2)           | −0.094       | −0.198, 0.009                 | 0.0           | 0.424               | < 0.001                             |
|                     | ≤ 55 (3)           | −1.816       | −2.809, −0.824                | 96.8          | < 0.001             |                                     |
| Participants’ condition | With CVD (3) | −0.435       | −1.013, 0.144                 | 85.8          | 0.001               | < 0.001                             |
|                     | Without CVD (2)    | −2.321       | −2.879, −1.762                | 86.9          | 0.006               |                                     |

CVD, cardiovascular disease; CI, confidence interval; hs-CRP, high sensitivity C-reactive protein.

*Calculated by random effects model.

Figure 2. Forest plot of the effect of Pycnogenol supplementation on C-reactive protein. ES, effect size; CI, confidence interval.
CRP as one of the most important evaluating inflammatory markers of atherosclerosis predominantly synthesized in the liver in response to proinflammatory cytokines, especially IL-6, IL-1β, and TNF-α [28]. This acute-phase reactant directly increases the degradation of several NF-κB inhibitor proteins and subsequently activates the NF-κB pathway. Furthermore, in a 2-way communication, the NF-κB heterodimeric p50/p65 can cause CRP mRNA accumulation. Additionally, it can stimulate endogenous synthesis of CRP and can have synergistic effect with IL-1β and IL-6 on CRP production signaling. Therefore, the suppression of NF-κB pathway is a crucial target to alleviate inflammation via inhibition of CRP production [29].

According to the result of previous studies, Pycnogenol has multiple roles in decreasing CRP level and are related to the suppression of NF-κB gene expression [14]. It has been proved that Pycnogenol has a significant NF-κB production-lowering effect in peripheral blood monocytes and to play a role in the reduction of TNF-α [4]. In a recent study, researchers have found that Pycnogenol has a significant repression effect on receptor activator of NF-κB ligand (RANKL) expression. However, it is important that Pycnogenol doesn't have any effect on RANKL-induced NF-κB [30]. Due to Pycnogenol's anti-oxidative characteristics and abilities to scavenge free radicals by neutralizing reactive oxygen, it may prevent from activating of NF-κB and play an anti-inflammatory effect [31]. In one study Pycnogenol could significantly attenuate IL-6, IL-1β, and TNF levels and then reduce synthesis of CRP in liver and decrease plasma level [32].

Based on reported evidence, no toxicity or mutagenic effects were detected after oral administration of Pycnogenol and it was considered as a safe dietary supplement in the USA [33]. A safety assessment of Pycnogenol supplementation based on 104 clinical studies suggested that the rate of adverse effects in subjects who consumed Pycnogenol was 1.66% [33]. Some of the most common side effects were mild and transient gastrointestinal troubles, dizziness, nausea, headache, and skin sensation [4]. Gastrointestinal discomfort was minimized when Pycnogenol was taken with breakfast [4].

This meta-analysis had the following several limitations: limited eligible clinical trials for assessing the effects of Pycnogenol on CRP; different doses of Pycnogenol and different duration of treatment periods; some of the included trials were not randomized or blinded; and the supplementation was conducted on different diseases. Unavailability of adjustment for potential confounders in some of the study analyse and no investigation for dietary intake in participants during follow-up could have potentially affected the findings of the included studies. Moreover, high heterogeneity of the results can be attributed to duration of intervention, study design, dosage of supplement, type of CRP marker, and participant's conditions in various studies. In order to recognize the source of heterogeneity, we performed various subgroup analysis. The results of subgroup analysis revealed that the heterogeneity was attenuated in dosage and age above 150 mg/d and 55 years, respectively. However, due to the high heterogeneity of our results, interpretation of these results should be cautiously under taken.

Present meta-analysis pooled results from 5 randomized clinical trials about the effect of Pycnogenol supplementation on CRP level. The results showed Pycnogenol consumption can decrease the level of CRP and has anti-inflammatory effect. Larger randomize clinical trial with long duration of treatment are needed to confirm the anti-inflammatory effect of Pycnogenol.
REFERENCES

1. Van Thuyne W, Van Eenoo P, Delbeke F. Nutritional supplements: prevalence of use and contamination with doping agents. Nutr Res Rev 2006;19:147-58. 
PUBMED | CROSSREF

2. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, Kessler RC. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998;280:1569-75. 
PUBMED | CROSSREF

3. Kobayashi MS, Han D, Packer L. Antioxidants and herbal extracts protect HT-4 neuronal cells against glutamate-induced cytotoxicity. Free Radic Res 2000;32:115-24. 
PUBMED | CROSSREF

4. Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther 2002;40:158-68. 
PUBMED | CROSSREF

5. Packer L, Rimbach G, Virgili F. Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, pycnogenol. Free Radic Biol Med 1999;27:704-24. 
PUBMED | CROSSREF

6. Dragnetoff G. Die heilpflanzen der verschiedensten völker und zeiten: ihre anwendung, wesentlichen bestandtheile und geschichte. Ein handbuch für ärzte, apotheker, botaniker und droguisten. Stuttgart: Ferdinand Enke; 1898.

7. Blazso G, Gábor M, Rohdewald P. Antiinflammatory activities of procyanidin-containing extracts from Pinus pinaster Ait. after oral and cutaneous application. Pharmazie 1997;52:380-2.

8. Devaraj S, Vega-López S, Kaul N, Schönlau F, Rohdewald P, Jialal I. Supplementation with a pine bark extract rich in polyphenols increases plasma antioxidant capacity and alters the plasma lipoprotein profile. Lipids 2002;37:931-4.

9. Majno G, Joris I. Cells, tissues, and disease: principles of general pathology. 2nd ed. New York (NY): Oxford University Press; 2004.

10. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008;454:428-35. 
PUBMED | CROSSREF

11. Nehringer SM, Bhimji SS. C reactive protein (CRP). Treasure Island (FL): StatPearls Publishing; 2017.

12. Yamashita H, Shimada K, Seki E, Mokuno H, Daida H. Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris. Am J Cardiol 2003;91:133-6. 
PUBMED | CROSSREF

13. Ticinesi A, Lauretani F, Nouvenne A, Porro E, Fanelli G, Maggio M, Meschi T. C-reactive protein (CRP) measurement in geriatric patients hospitalized for acute infection. Eur J Intern Med 2017;37:742. 
PUBMED | CROSSREF

14. Peng Q, Wei Z, Lau BH. Pycnogenol inhibits tumor necrosis factor-α-induced nuclear factor kappa B activation and adhesion molecule expression in human vascular endothelial cells. Cell Mol Life Sci 2000;57:834-41. 
PUBMED | CROSSREF

15. Belcaro G, Cornelli U, Luzzi R, Cesarone MR, Dugall M, Feragalli B, Errichi S, Ippolito E, Grossi MG, Hosoi M, Cornelli M, Gizzi G. Pycnogenol® supplementation improves health risk factors in subjects with metabolic syndrome. Phytother Res 2013;27:1572-8.

16. Luzzi R, Belcaro G, Hosoi M, Feragalli B, Cornelli U, Dugall M, Ledda A. Normalization of cardiovascular risk factors in peri-menopausal women with Pycnogenol®. Minerva Ginecol 2017;69:29-34.

17. Belcaro G, Cesarone MR, Errichi S, Zulli C, Errichi BM, Vinciguerra G, Ledda A, Di Renzo A, Stuard S, Dugall M, Pelegrini L, Gizzi G, Ippolito E, Ricci A, Cacchio M, Cipollone G, Ruffini I, Fano F, Hosoi M, Rohdewald P. Variations in C-reactive protein, plasma free radicals and fibrinogen values in patients with osteoarthritis treated with Pycnogenol. Redox Rep 2008;13:271-6. 
PUBMED | CROSSREF

18. Schiffer A, Chovanová Z, Muchová J, Sumegová K, Liptákovičová A, Duracková Z, Högger P. Inhibition of COX-1 and COX-2 activity by plasma of human volunteers after ingestion of French maritime pine bark extract (Pycnogenol). Biomed Pharmacother 2006;60:5-9. 
PUBMED | CROSSREF
19. Enseleit F, Sudano I, Periat D, Winnik S, Wolfrum M, Flammer AJ, Fröhlich GM, Kaiser P, Hirt A, Haile SR, Krasniqi N, Matter CM, Uhlenhut K, Högger P, Neidhart M, Lüscher TF, Ruschitzka F, Noll G. Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study. Eur Heart J 2012;33:1589-97. 
PUBMED | CROSSREF

20. Tang Y, Fang E, Xu A, Lan HY. C-reactive protein and ageing. Clin Exp Pharmacol Physiol 2017;44 Suppl 1:9-14. 
PUBMED | CROSSREF

21. Picot J, Hartwell D, Harris P. The preferred reporting items for systematic reviews and meta-analyses checklist. Southampton: NIHR Journals Library; 2012.

22. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:31-42. 
PUBMED | CROSSREF

23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. 
PUBMED | CROSSREF

24. Cesaroni MR, Belcaro G, Stuard S, Schönlaub F, Di Renzo A, Grossi MG, Dugall M, Cornelli U, Cacchio M, Gizzetti GB, Pellegrini L. Kidney flow and function in hypertension: protective effects of Pycnogenol in hypertensive participants—a controlled study. J Cardiovasc Pharmacol Ther 2010;15:41-6. 
PUBMED | CROSSREF

25. Drieling RL, Gardner CD, Ma J, Ahn DK, Stafford RS. No beneficial effects of pine bark extract on cardiovascular disease risk factors. Arch Intern Med 2010;170:1541-7. 
PUBMED | CROSSREF

26. Hayden MS, Ghosh S. Regulation of NF-κB by TNF family cytokines. Semin Immunol 2014;26:253-66. 
PUBMED | CROSSREF

27. Jin X, Chen M, Yi L, Chang H, Zhang T, Wang L, Ma W, Peng X, Zhou Y, Mi M. Delphinidin-3-glucoside protects human umbilical vein endothelial cells against oxidized low-density lipoprotein-induced injury by autophagy upregulation via the AMPK/SIRT1 signaling pathway. Mol Nutr Food Res 2014;58:1941-51. 
PUBMED | CROSSREF

28. Salazar J, Martínez MS, Chávez-Castillo M, Núñez V, Áñez R, Torres Y, Toledo A, Chacín M, Silva C, Pacheco E, Rojas J, Bermúdez V. C-reactive protein: an in-depth look into structure, function, and regulation. Int Sch Res Notices 2014;2014:653045. 
PUBMED

29. Agrawal A, Cha-Molstad H, Samols D, Kushner I. Overexpressed nuclear factor-kappaB can participate in endogenous C-reactive protein induction, and enhances the effects of C/EBPβ and signal transducer and activator of transcription-3. Immunology 2003;108:539-47. 
PUBMED | CROSSREF

30. Watanabe H, Fan B, Ikuyama S. Pycnogenol, a French maritime pine extract, suppresses RANKL-stimulated osteoclast differentiation of RAW264.7 cells. The Endocrine Society's 93rd Annual Meeting & Expo; 2011 Jun 4-7; Boston, MA, Washington, D.C.: Endocrine Society; 2011. P1-191.

31. Rohdewald P. Pycnogenol®, French maritime pine bark extract. In: Coates PM, editor. Encyclopedia of dietary supplements. 2nd ed. New York (NY): Marcel Dekker; 2005. p. 545-53.

32. Fan B, Dun SH, Gu JQ, Guo Y, Ikuyama S. Pycnogenol attenuates the release of proinflammatory cytokines and expression of perilipin 2 in lipopolysaccharide-stimulated microglia in part via inhibition of NF-κB and AP-1 activation. PLoS One 2015;10:e0137837. 
PUBMED | CROSSREF

33. Gulati OP. Pycnogenol(R) in chronic venous insufficiency and related venous disorders. Phytother Res 2014;28:348-62. 
PUBMED | CROSSREF

https://e-cnr.org  https://doi.org/10.7762/cnr.2018.7.2.117  125